Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Capucine Baldini1, Patricia Martin Romano1, Andreea Varga1

  • 1Gustave-Roussy, université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France.

Bulletin Du Cancer
|January 1, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Collective cell migration plasticity in patient-derived digestive cancer organoids is dictated by environment sensing and contractility.

Cell reports·2026
Same author

Predicting survival of patients treated with antibody-drug conjugates in early-phase clinical trials using AI-quantified 3D body composition on CT scans.

Frontiers in oncology·2026
Same author

Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study.

European journal of cancer (Oxford, England : 1990)·2026
This summary is machine-generated.

Immunotherapy shows promise for solid tumors, but its effectiveness in glioblastomas is still under investigation. Understanding the central nervous system

Area of Science:

  • Neuro-oncology
  • Immunology
  • Cancer Therapy

Background:

  • Immunotherapy is effective in solid tumors.
  • Glioblastomas (GBM) treatment remains challenging.
  • The central nervous system (CNS) is not fully immunoprivileged.

Purpose of the Study:

  • To review the CNS immune system.
  • To explore immunotherapy strategies for GBM.
  • To understand CNS immune privilege.

Main Methods:

  • Literature review of CNS immunology.
  • Analysis of current immunotherapy research in GBM.
  • Discussion of immune privilege mechanisms.

Main Results:

  • The CNS exhibits a complex immune environment.
Keywords:
CNSGlioblastomaGlioblastomeImmune checkpointImmunotherapyImmunothérapieInhibiteurs du pointSNCde contrôleimmunitaireinhibitors

Related Experiment Videos

  • GBM can evade immune responses.
  • Emerging immunotherapies show potential.

    • Conclusions:

    • Further research into CNS immunity is crucial for GBM treatment.
    • Targeting the immune system offers a promising avenue for glioblastoma therapy.